Ecarin is derived from venom of Echis carinatus and will activate prothrombin into meizothrombin which will then cleave fibrinogen to result in clot formation. Ecarin based testing has been described […]» Read more
The SARS-CoV-2 coronavirus (COVID-19) induced infection can be associated with a coagulopathy, findings consistent with infection induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack […]» Read more
Although the pathophysiology underlying severe COVID-19 remains poorly understood, accumulating data suggest that a lung-centric coagulopathy may play an important role. Elevated D-dimer levels which correlated inversely with overall survival […]» Read more
Lupus anticoagulants (LA) are heterogeneous antibodies and no single assay will detect every LA. Consequently, testing is commonly undertaken with both dilute Russell’s viper venom time (dRVVT) and LA-responsive activated […]» Read more
Changes in Blood Coagulation in Patients with Severe Coronavirus Disease 2019 (COVID-19): a Meta-Analysis.
Coronavirus disease 2019 (COVID-19) is widely spread and poses a critical threat to global health (Zhang et al). Prominent changes in coagulation function in severe patients of COVID-19 have been […]» Read more
Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.
Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. […]» Read more
Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.
Anticoagulant protein S (PS) in platelets (PSplt) resembles plasma PS and is released upon platelet activation; but its role in thrombosis has not been elucidated. Here we report that inactivation […]» Read more
The roles of anticoagulation alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI) have not been well studied.We performed a randomized trial of clopidogrel in patients undergoing TAVI […]» Read more
Diagnosis of suspected recurrent ipsilateral deep vein thrombosis with magnetic resonance direct thrombus imaging.
The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) is challenging because persistent intravascular abnormalities after previous DVT often hinder a diagnosis by compression ultrasonography. Magnetic resonance direct thrombus imaging […]» Read more
Bacterial infection not only stimulates innate immune responses but also activates the coagulation cascades. Over-activation of the coagulation system in bacterial sepsis leads to disseminated intravascular coagulation (DIC), a life-threatening […]» Read more
Seronegative antiphospholipid syndrome: refining the value of non-criteria antibodies for the diagnosis and clinical management.
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial and venous thrombotic manifestations and/or pregnancy-related complications in patients with persistently high antiphospholipid antibodies (aPL), the most common being […]» Read more
Alternative activation of human macrophages enhances tissue factor expression and production of extracellular vesicles.
Macrophages are versatile cells that can be polarized by the tissue environment to fulfill required needs. Proinflammatory polarization is associated with increased tissue degradation and propagation of inflammation whereas alternative […]» Read more
CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs.
Hemophilia B is an X-linked recessive bleeding disorder caused by abnormalities in the coagulation factor IX gene. Without prophylactic treatment, patients experience frequent spontaneous bleeding episodes. Well-characterized animal models are […]» Read more
Protein C activator AB002 rapidly interrupts thrombus development in baboons and appears safe in a first-in-human trial.
While thrombin is a key enzyme in the coagulation cascade and is required for both normal hemostasis and pathologic thrombogenesis, it also participates in its own negative feedback via activation […]» Read more
Obesity has become a major threat to health worldwide. The prevalence of obesity is rapidly increasing, so much so that the World Health Organization has declared obesity as global epidemic. […]» Read more
Thrombin-mediated activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease.
Vaso-occlusive crisis (VOC) is the primary cause of morbidity and hospitalization in sickle cell disease (SCD). However, only three therapies (hydroxyurea, L-glutamine, and crizanlizumab) are currently approved in SCD. These […]» Read more
Red Blood Cell Microvesicles Activate The Contact System Leading To Factor IX Activation Via Two Independent Pathways.
Storage lesion-induced red cell-derived microvesicles (RBC-MVs) propagate coagulation by supporting the assembly of the prothrombinase complex. It has also been reported that RBC-MVs initiate coagulation via the intrinsic pathway. To […]» Read more
Acetylsalicylic acid (ASA) inhibits intravascular coagulation during S. aureus-induced sepsis in mice.
Anti-platelet therapies have been proposed for the treatment of sepsis, a syndrome resulting from a dysregulated immune response and inappropriate activation of coagulation. Acetylsalicylic acid (ASA) may serve as a […]» Read more
How I assess and manage the risk of bleeding during treatment of patients with venous thromboembolism.
For patients with venous thromboembolism (VTE), prediction of bleeding is relevant throughout the course of treatment, although the means and goal of this prediction differ between the subsequent stages of […]» Read more
While we are now able to diagnose inherited thrombophilias in a substantial number of patients with venous thromboembolism (VTE), the initial hope that their presence would inform recurrence risk and […]» Read more
Venous thrombosis rarely occurs at unusual sites such as cerebral, splanchnic, upper extremity, renal, ovarian or retinal veins. Clinical features, symptoms and risk factors of rare thrombotic manifestations are heterogeneous […]» Read more
Venous thromboembolism (VTE) is rare in healthy children,but an increasing problem in children with underlying medical conditions. Pediatric VTE encompasses a highly heterogenous population, with variation in age, thrombosis location […]» Read more
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of vascular death after heart attack and stroke. Anticoagulation therapy is […]» Read more
The most important decision in the long-term treatment of VTE is how long to anticoagulate. VTE provoked by a reversible risk factor, or a first unprovoked isolated distal DVT, generally […]» Read more
All patients with venous thromboembolism should receive anticoagulant treatment in the absence of absolute contraindications. Initial anticoagulant treatment is crucial to reduce mortality, prevent early recurrences and improve long-term outcome. […]» Read more
Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.
The antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies including anti-beta-2-glycoprotein-I (anti-β2GPI) that are considered central to APS pathogenesis. Based on animal […]» Read more
This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children […]» Read more
From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
Thrombotic and hemorrhagic complications are prevalent in patients with essential thrombocythemia, polycythemia vera, and myelofibrosis. Given the impact on morbidity and mortality, reducing the risk of thrombosis and/or hemorrhage is […]» Read more